EP Patent

EP4265299A3 — Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Assigned to Gilead Sciences Inc · Expires 2024-01-17 · 2y expired

What this patent protects

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

USPTO Abstract

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Drugs covered by this patent

Patent Metadata

Patent number
EP4265299A3
Jurisdiction
EP
Classification
Expires
2024-01-17
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.